1. Class action lawsuit filed against Viatris citing securities fraud. 2. Stock price dropped 15.21% after missing financial targets. 3. Lower-than-expected 2025 guidance reported by Viatris. 4. Remediation efforts underway at FDA-warned manufacturing facility in India. 5. Investors can join the class action until June 3, 2025.
The class action lawsuit signifies potential legal troubles, affecting investor confidence. Historical examples show that such lawsuits often result in stock price declines until resolved.
The lawsuit could lead to significant financial liabilities for VTRS, negatively impacting its stock price and investor trust. This relevance is amplified by the recent stock performance.
The impending legal issues and recent stock drop will likely affect VTRS's price in the near future. Immediate investor sentiment will be relevant until further developments emerge.
Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at danielle.payton@example.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Viatris and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until June 3, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Viatris securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
Click here for information about joining the class action
On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. In addition, Viatris provided lower-than-expected full-year guidance for 2025. Viatris also provided an update on remediation work at a manufacturing facility in India following receipt of a warning letter and import alert from the U.S. Food and Drug Administration, advising that it was "more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility."
On this news, Viatris's stock price fell $1.71 per share, or 15.21%, to close at $9.53 per share on February 27, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Danielle Peyton Pomerantz LLP danielle.payton@example.com 646-581-9980 ext. 7980
SOURCE Pomerantz LLP